{ "schemaVersion": 2, "eyebrow": "Endocrinology", "title": "DKA Transition to Subcutaneous Insulin", "summary": "Transition from intravenous to subcutaneous insulin only after ketoacidosis has resolved, oral intake is adequate, and basal insulin timing prevents an interruption in insulin activity. Use a structured overlap, meal-linked prandial dosing, and post-transition glucose surveillance to limit rebound hyperglycemia and recurrent DKA.", "seoDescription": "Physician guidance for transitioning DKA from IV insulin to subcutaneous basal-bolus therapy, including resolution criteria, overlap, meals, and monitoring.", "clinicalQuestion": "How should clinicians safely transition a patient with resolved diabetic ketoacidosis from intravenous to subcutaneous insulin?", "specialty": "Endocrinology", "audience": "U.S. physicians and medical trainees", "tags": [ "diabetic ketoacidosis", "DKA transition", "intravenous insulin", "subcutaneous insulin", "basal insulin overlap", "rebound hyperglycemia" ], "keyTakeaways": [ "Do not stop intravenous insulin for glucose control alone; continue it until ketoacidosis has resolved, with dextrose-containing fluid and/or insulin-rate reduction as glucose falls. [20][21]", "For patients not receiving basal insulin during the infusion, administer subcutaneous insulin and maintain IV insulin for at least 1-2 hours to avoid an insulin gap. [14][18][21]", "Coordinate transition with a meal when possible; resume or initiate rapid-acting insulin with meals once DKA has resolved and oral intake is adequate. [7][8][21]", "Continue a patient’s preadmission long-acting insulin during IV insulin when feasible; for newly diagnosed patients, basal insulin initiation of 0.15-0.3 units/kg is described. [21]", "Early basal insulin given with IV insulin can reduce rebound hyperglycemia without an observed increase in hypoglycemia, but potassium surveillance remains essential. [3][17][20]" ], "sections": [ { "id": "confirm-readiness", "eyebrow": "Before stopping IV insulin", "heading": "Confirm biochemical resolution and clinical readiness", "intro": "Transition is a treatment change, not simply an IV-line discontinuation.", "paragraphs": [ "Continue fixed-rate IV insulin until ketoacidosis has resolved rather than stopping when glucose normalizes. Endotext defines resolution by pH greater than 7.3, bicarbonate at least 18 mmol/L, and plasma ketones below 0.6 mmol/L; anion-gap normalization is also used in transition protocols. [14][21]", "Assess oral intake before converting to a standard basal-bolus regimen. Once DKA has resolved and oral intake is adequate, discontinue IV insulin after appropriate subcutaneous coverage and give or resume rapid-acting insulin with meals. If oral intake remains poor, use a variable-rate insulin infusion with glucose-containing solutions rather than an unprotected transition to meal-based subcutaneous insulin. [21]", "A falling glucose concentration does not establish DKA resolution. When glucose falls below 250 mg/dL, reduce the IV insulin rate to 0.05 units/kg/hour and continue insulin with a glucose target of about 200 mg/dL while ketoacidosis clears; dextrose-containing fluids permit continued anti-ketogenic insulin delivery. [20][21]" ], "bullets": [ "Before transition, document pH, bicarbonate, serum ketones when available, anion gap, bedside glucose, potassium, and ability to eat. Resolution markers determine whether IV insulin can stop; potassium and glucose determine how safely it can continue. [14][19][21]", "For an intended meal-based transition, arrange administration of rapid-acting insulin before the meal rather than waiting until after food intake. [7][8][21]" ], "subsections": [], "table": { "caption": "Operational criteria for IV-to-SC insulin transition in DKA. [14][21]", "columns": [ "Decision point", "Action" ], "rows": [ [ "Ketoacidosis not resolved", "Continue IV insulin; use dextrose-containing fluid and/or lower the infusion rate as glucose falls rather than stopping insulin. [20][21]" ], [ "pH >7.3, bicarbonate ≥18 mmol/L, and plasma ketones <0.6 mmol/L", "DKA is resolved by Endotext criteria; proceed to planned SC coverage if the patient can take oral nutrition. [21]" ], [ "Oral intake adequate", "Give or resume rapid-acting insulin with meals and establish basal insulin coverage before stopping IV insulin. [7][8][21]" ], [ "Oral intake poor", "Use variable-rate IV insulin with glucose solutions instead of a routine meal-based SC transition. [21]" ] ] } }, { "id": "build-sc-regimen", "eyebrow": "Regimen selection", "heading": "Establish basal insulin before removing IV insulin coverage", "intro": "The central safety task is avoiding a period without effective insulin.", "paragraphs": [ "For patients already taking long-acting insulin before admission, continue basal insulin during IV insulin treatment when feasible. This preserves basal coverage and facilitates transition to a basal-bolus regimen once ketoacidosis resolves. [21]", "For a newly diagnosed patient, initiate basal insulin at 0.15-0.3 units/kg as part of transition planning. Add rapid-acting insulin with meals only after DKA resolution and adequate oral intake. [21]", "If basal insulin was not administered during the IV insulin course, give the planned subcutaneous insulin dose and continue IV insulin for at least 1-2 additional hours. An electronic transition intervention specifically targeted IV insulin discontinuation without long-acting insulin in the prior 2-6 hours and reinforced a minimum 2-hour overlap. [14][18][21]" ], "bullets": [ "Known diabetes: return to the prior home insulin regimen when clinically appropriate, then adjust for inpatient glucose control. [14]", "New diabetes: prescribe a basal regimen before IV discontinuation, then pair it with prandial rapid-acting insulin when meals resume. [21]", "Do not rely on correction-only insulin as the sole bridge after IV insulin is stopped; planned basal coverage is required to prevent an interruption in insulin action. [14][18][21]" ], "subsections": [], "table": { "caption": "Subcutaneous insulin transition pathways. [14][18][21]", "columns": [ "Clinical situation", "Subcutaneous plan", "IV insulin stop timing" ], "rows": [ [ "Long-acting insulin used before admission", "Continue basal insulin during IV treatment; resume rapid-acting insulin with meals after resolution and adequate intake. [21]", "Discontinue after DKA resolution and transition plan is active. [21]" ], [ "No basal insulin given during IV treatment", "Administer planned SC insulin, including basal coverage. [14][18][21]", "Maintain IV insulin for at least 1-2 hours after SC administration. [14][18][21]" ], [ "Newly diagnosed diabetes", "Initiate basal insulin 0.15-0.3 units/kg; add meal-associated rapid-acting insulin when eating. [21]", "Use the same 1-2-hour overlap if basal insulin was not already coadministered. [21]" ], [ "Poor oral intake", "Use variable-rate IV insulin plus glucose solutions. [21]", "Do not convert to a routine meal-based SC regimen until intake is adequate. [21]" ] ] } }, { "id": "early-basal-insulin", "eyebrow": "During IV treatment", "heading": "Consider early basal insulin to simplify transition", "intro": "Early basal insulin is an adjunct to—not a replacement for—IV insulin during active DKA.", "paragraphs": [ "Coadministration of long-acting basal insulin during IV insulin infusion is increasingly used. Trials summarized in a randomized-trial report found that glargine U-100 at 0.15-0.3 units/kg during IV insulin was associated with shorter time to DKA resolution, shorter IV insulin duration, shorter hospital stay, and less rebound hyperglycemia without increased hypoglycemia. [3]", "A systematic review and meta-analysis of randomized trials found no evidence that early basal insulin increased hypoglycemia; pooled hypokalemia rates were not significantly different, although a trend toward more hypokalemia was observed. Continue potassium monitoring because hypokalemia occurs in up to 55% of DKA cases. [17]", "Early basal insulin is most useful when a predictable transition to basal-bolus therapy is expected or when failure to overlap insulin is a recurrent systems problem. It does not permit premature discontinuation of IV insulin: continue the infusion until biochemical DKA resolution. [17][20][21]" ], "bullets": [ "Early basal option reported in trials: insulin glargine U-100, 0.15-0.3 units/kg subcutaneously during IV insulin infusion. [3]", "For newly diagnosed patients, the same 0.15-0.3 units/kg basal starting range is described in transition guidance. [21]", "Monitor potassium closely during concurrent insulin therapy; insulin-related intracellular electrolyte shifts can produce hypokalemia. [17][19]" ], "subsections": [], "table": { "caption": "Early basal insulin: practical tradeoff. [3][17][20][21]", "columns": [ "Potential advantage", "Required safeguard" ], "rows": [ [ "May reduce rebound hyperglycemia and shorten IV insulin exposure. [3][20]", "Do not stop IV insulin until ketoacidosis has resolved. [20][21]" ], [ "Avoids a late transition insulin gap when basal insulin is given during the infusion. [21]", "Continue serial potassium assessment; hypokalemia is common during DKA treatment. [17]" ], [ "No increased hypoglycemia signal in pooled randomized-trial data. [17]", "Continue frequent bedside glucose monitoring while IV insulin remains active. [19][20]" ] ] } }, { "id": "monitor-after-transition", "eyebrow": "Post-transition surveillance", "heading": "Detect rebound hyperglycemia, hypoglycemia, and recurrent ketosis", "intro": "The highest-risk errors occur when overlap, meal timing, and IV dextrose are changed simultaneously.", "paragraphs": [ "During IV insulin therapy, check bedside glucose hourly and obtain serial basic metabolic testing to follow bicarbonate, anion gap, potassium, magnesium, and phosphate. These measurements identify persistent ketoacidosis and insulin-associated electrolyte shifts before transition. [19][20]", "At conversion, explicitly reconcile three orders: long-acting insulin administration, IV insulin stop time, and dextrose-containing fluid discontinuation. A quality-improvement protocol used a mandatory checklist for at least 2 hours of IV/SC overlap and guidance on stopping IV dextrose-containing fluids to reduce post-transition dysglycemia. [18]", "Treat post-transition glucose excursions as a possible coverage failure rather than assuming DKA has recurred. Reassess whether basal insulin was administered, whether there was a 1-2-hour overlap, whether prandial insulin matched nutrition, and whether biochemical resolution was documented before the infusion was stopped. [14][18][21]" ], "bullets": [ "Hourly bedside glucose monitoring is standard during active IV insulin infusion. [19][20]", "Hypoglycemia is defined as blood glucose below 70 mg/dL in the cited transition study; correct promptly and reassess insulin and dextrose orders. [19]", "If anion gap, bicarbonate, or ketones worsen after IV insulin discontinuation, restart evaluation for recurrent or incompletely resolved ketoacidosis and restore continuous insulin coverage as indicated. [14][19][21]" ], "subsections": [], "table": { "caption": "Transition-order checklist and response to abnormal findings. [14][18][19][21]", "columns": [ "Check", "Finding", "Next action" ], "rows": [ [ "Biochemical status before IV stop", "DKA resolution criteria not met. [21]", "Continue IV insulin with glucose support as needed; do not complete transition. [20][21]" ], [ "Basal insulin administration", "No basal insulin during infusion. [14][18][21]", "Give SC insulin and maintain IV insulin for at least 1-2 hours. [14][18][21]" ], [ "Nutrition", "Unable to eat reliably. [21]", "Use variable-rate IV insulin with glucose solutions. [21]" ], [ "Post-transition glucose", "Blood glucose <70 mg/dL. [19]", "Treat hypoglycemia promptly and reassess insulin and dextrose orders. [19]" ], [ "Post-transition metabolic panel", "Reopening anion gap or worsening bicarbonate/ketones. [14][19][21]", "Evaluate for persistent or recurrent ketoacidosis and restore continuous insulin coverage as clinically indicated. [14][19][21]" ] ] } } ], "faq": [], "references": [ { "number": 1, "title": "Diabetic Ketoacidosis Management in Pediatric Populations | Endocrinology | Clinical Sciences | Health sciences | Topics | Nature Index", "detail": "www.nature.com", "url": "https://www.nature.com/nature-index/topics/l4/diabetic-ketoacidosis-management-in-pediatric-populations", "authors": "www.nature.com", "host": "www.nature.com" }, { "number": 2, "title": "2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection ...", "detail": "www.ahajournals.org", "url": "https://www.ahajournals.org/doi/pdf/10.1161/CIR.0000000000001453?download=true", "authors": "www.ahajournals.org", "host": "www.ahajournals.org" }, { "number": 3, "title": "Early insulin degludec with continuous... : Diabetes, Obesity and Metabolism", "detail": "journals.lww.com", "url": "https://journals.lww.com/00127973-202512000-00019", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 4, "title": "Early versus late initiation of long-acting... : Diabetes, Obesity ... - Ovid", "detail": "journals.lww.com", "url": "https://journals.lww.com/00127973-202605000-00022", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 5, "title": "Estimated Cost-effectiveness of Subcutaneous... : JAMA Network Open", "detail": "journals.lww.com", "url": "https://journals.lww.com/02093599-202209000-00026", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 6, "title": "Effectiveness and safety of early insulin... : Diabetes, Obesity and Metabolism", "detail": "journals.lww.com", "url": "https://journals.lww.com/00127973-202303000-00020", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 7, "title": "Management of Diabetic Ketoacidosis in Children and Adolescents", "detail": "publications.aap.org", "url": "https://publications.aap.org/pediatricsinreview/article/29/12/431/33976/Management-of-Diabetic-Ketoacidosis-in-Children", "authors": "publications.aap.org", "host": "publications.aap.org" }, { "number": 8, "title": "25: Diabetic Ketoacidosis - AAP Publications", "detail": "publications.aap.org", "url": "https://publications.aap.org/aapbooks/book/676/chapter/8134877/Diabetic-Ketoacidosis", "authors": "publications.aap.org", "host": "publications.aap.org" }, { "number": 9, "title": "Does the Addition of Subcutaneous Basal Insulin Administration ...", "detail": "www.annemergmed.com", "url": "https://www.annemergmed.com/article/S0196-0644(26)00075-2/fulltext", "authors": "www.annemergmed.com", "host": "www.annemergmed.com" }, { "number": 10, "title": "Diabetes, Diabetic Ketoacidosis, and Type 2 Diabetes | AAP Books", "detail": "publications.aap.org", "url": "https://publications.aap.org/aapbooks/edited-volume/736/chapter/11706043/Diabetes-Diabetic-Ketoacidosis-and-Type-2-Diabetes", "authors": "publications.aap.org", "host": "publications.aap.org" }, { "number": 11, "title": "Subcutaneous rapid‐acting insulin analogues for diabetic ketoacidosis", "detail": "www.cochranelibrary.com", "url": "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011281.pub2/full", "authors": "www.cochranelibrary.com", "host": "www.cochranelibrary.com" }, { "number": 12, "title": "Diabetic Ketoacidosis (Chapter 354) - AAP Publications", "detail": "publications.aap.org", "url": "https://publications.aap.org/pediatriccare/book/348/chapter/5788504/Diabetic-Ketoacidosis-Chapter-354", "authors": "publications.aap.org", "host": "publications.aap.org" }, { "number": 13, "title": "Managing Diabetic Ketoacidosis in Children", "detail": "www.annemergmed.com", "url": "https://www.annemergmed.com/article/S0196-0644(21)00160-8/fulltext", "authors": "www.annemergmed.com", "host": "www.annemergmed.com" }, { "number": 14, "title": "[PDF] Clinical Practice Guidelines and Standards of Care of Diabetes ...", "detail": "extranet.who.int", "url": "https://extranet.who.int/ncdccs/Data/sdn_D1_final_Sudan_Diabetes_Guideline_2011%20(2).pdf", "authors": "extranet.who.int", "host": "extranet.who.int" }, { "number": 15, "title": "Pemphigus Vulgaris Complicated by SGLT-2 Inhibitor Associated Euglycemic Diabetic Ketoacidosis | ACS", "detail": "www.facs.org", "url": "https://www.facs.org/for-medical-professionals/news-publications/journals/case-reviews/issues/v5n5/12-stevens-diabetic-ketoacidosis", "authors": "www.facs.org", "host": "www.facs.org" }, { "number": 16, "title": "[PDF] Pemphigus Vulgaris Complicated by SGLT-2 Inhibitor Associated ...", "detail": "www.facs.org", "url": "https://www.facs.org/media/ze5da444/12-stevens-diabetic-ketoacidosis.pdf", "authors": "www.facs.org", "host": "www.facs.org" }, { "number": 17, "title": "Early subcutaneous basal insulin with intravenous insulin infusion for diabetic ketoacidosis management: A systematic review and meta‐analysis of randomised controlled trials - PMC", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12803681", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" }, { "number": 18, "title": "Improving Intravenous and Subcutaneous Insulin Overlap During Treatment of Diabetic Ketoacidosis: A Quality Improvement Project", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11141259", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" }, { "number": 19, "title": "Success of Insulin Infusion Transitions in Moderate to Severe Diabetic Ketoacidosis With Transition Anion Gap of Less Than or Equal to 12 mEq/L Versus Greater Than 12 mEq/L", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11097940", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" }, { "number": 20, "title": "Management of adult diabetic ketoacidosis - PMC - NIH", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4085289", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" }, { "number": 21, "title": "Diabetic Ketoacidosis - Endotext - NCBI Bookshelf", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/books/NBK620701", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov" }, { "number": 22, "title": "Basal insulin for the management of diabetic ketoacidosis", "detail": "pubmed.ncbi.nlm.nih.gov", "url": "https://pubmed.ncbi.nlm.nih.gov/28864157", "authors": "pubmed.ncbi.nlm.nih.gov", "host": "pubmed.ncbi.nlm.nih.gov" }, { "number": 23, "title": "Diabetes and Hypertension Management Manual 15 Mar 2011", "detail": "extranet.who.int", "url": "https://extranet.who.int/ncdccs/Data/DMA_B6_Diabetes%20and%20Hypertension%20Management%20Manual%2015%20Mar%202011-%20Final2[3].pdf", "authors": "extranet.who.int", "host": "extranet.who.int" }, { "number": 24, "title": "MANAGING DIABETES IN SAINT LUCIA - Extranet Systems", "detail": "extranet.who.int", "url": "https://extranet.who.int/ncdccs/Data/LCA_D1_SLUDiabetes2006.pdf", "authors": "extranet.who.int", "host": "extranet.who.int" } ], "editorialNote": "Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.", "citations": [ { "number": 1, "title": "Diabetic Ketoacidosis Management in Pediatric Populations | Endocrinology | Clinical Sciences | Health sciences | Topics | Nature Index", "detail": "www.nature.com", "url": "https://www.nature.com/nature-index/topics/l4/diabetic-ketoacidosis-management-in-pediatric-populations", "authors": "www.nature.com", "host": "www.nature.com", "snippet": "Diabetic ketoacidosis (DKA) is an acute metabolic emergency characterised by hyperglycaemia, ketonaemia and metabolic acidosis that predominantly affects children with type 1 diabetes. Early recognition of polyuria, polydipsia and weight loss is essential to prevent progression to dehydration, elect", "score": 0.7640656 }, { "number": 2, "title": "2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection ...", "detail": "www.ahajournals.org", "url": "https://www.ahajournals.org/doi/pdf/10.1161/CIR.0000000000001453?download=true", "authors": "www.ahajournals.org", "host": "www.ahajournals.org", "snippet": "DKA indicates diabetic ketoacidosis; consider slower dose titration for those experiencing GI challenges. Insulin dosing should be reassessed", "score": 0.39110413 }, { "number": 3, "title": "Early insulin degludec with continuous... : Diabetes, Obesity and Metabolism", "detail": "journals.lww.com", "url": "https://journals.lww.com/00127973-202512000-00019", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "Insulin therapy is one of the cornerstones of DKA management. Most patients are treated with a continuous intravenous infusion of regular insulin until DKA resolves, at which point they are transitioned to subcutaneous (SC) insulin.1 Early use of basal insulin in combination with intravenous insulin", "score": 0.58664185 }, { "number": 4, "title": "Early versus late initiation of long-acting... : Diabetes, Obesity ... - Ovid", "detail": "journals.lww.com", "url": "https://journals.lww.com/00127973-202605000-00022", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "Diabetic ketoacidosis (DKA) is a serious complication of diabetes, requiring intravenous (IV) insulin until resolution and subsequent transition to subcutaneous", "score": 0.53079647 }, { "number": 5, "title": "Estimated Cost-effectiveness of Subcutaneous... : JAMA Network Open", "detail": "journals.lww.com", "url": "https://journals.lww.com/02093599-202209000-00026", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "Intravenous (IV) insulin infusion is the standard of care for treating diabetic ketoacidosis (DKA) worldwide. Subcutaneous (SC) insulin aspart", "score": 0.462061 }, { "number": 6, "title": "Effectiveness and safety of early insulin... : Diabetes, Obesity and Metabolism", "detail": "journals.lww.com", "url": "https://journals.lww.com/00127973-202303000-00020", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "Advertisement\n\nOvid® Ovid Logo\n\nSearch Ovid Search Ovid\n\nBrowse Browse\n\nLogin Login\n\nDiabetes, Obesity and Metabolism\n\nNavbar\n\nMenu\n\n Current Issue \n Previous Issues \n Latest Articles \n\n More menu items \n\nSearch Journal Search Journal\n\nButton group.\n\n Check Access \n Image 1Permissi", "score": 0.26725978 }, { "number": 7, "title": "Management of Diabetic Ketoacidosis in Children and Adolescents", "detail": "publications.aap.org", "url": "https://publications.aap.org/pediatricsinreview/article/29/12/431/33976/Management-of-Diabetic-Ketoacidosis-in-Children", "authors": "publications.aap.org", "host": "publications.aap.org", "snippet": "It is best to make the transition from intravenous insulin to subcutaneous insulin at the time of a meal.", "score": 0.7306941 }, { "number": 8, "title": "25: Diabetic Ketoacidosis - AAP Publications", "detail": "publications.aap.org", "url": "https://publications.aap.org/aapbooks/book/676/chapter/8134877/Diabetic-Ketoacidosis", "authors": "publications.aap.org", "host": "publications.aap.org", "snippet": "The most convenient time to transition the patient to a subcutaneous (SC) insulin regimen is prior to a meal. Administer rapid-acting SC insulin approximately", "score": 0.6549173 }, { "number": 9, "title": "Does the Addition of Subcutaneous Basal Insulin Administration ...", "detail": "www.annemergmed.com", "url": "https://www.annemergmed.com/article/S0196-0644(26)00075-2/fulltext", "authors": "www.annemergmed.com", "host": "www.annemergmed.com", "snippet": "Early subcutaneous basal insulin with intravenous insulin infusion for diabetic ketoacidosis management: a systematic review and meta-analysis", "score": 0.5954225 }, { "number": 10, "title": "Diabetes, Diabetic Ketoacidosis, and Type 2 Diabetes | AAP Books", "detail": "publications.aap.org", "url": "https://publications.aap.org/aapbooks/edited-volume/736/chapter/11706043/Diabetes-Diabetic-Ketoacidosis-and-Type-2-Diabetes", "authors": "publications.aap.org", "host": "publications.aap.org", "snippet": "The most convenient time to transition the patient to a subcutaneous (SC) insulin regimen is prior to a meal. Administer rapid-acting SC insulin approximately", "score": 0.53094244 }, { "number": 11, "title": "Subcutaneous rapid‐acting insulin analogues for diabetic ketoacidosis", "detail": "www.cochranelibrary.com", "url": "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011281.pub2/full", "authors": "www.cochranelibrary.com", "host": "www.cochranelibrary.com", "snippet": "Five trials randomised 201 participants (110 participants to subcutaneous rapid‐acting insulin analogues and 91 to intravenous regular insulin).", "score": 0.44391435 }, { "number": 12, "title": "Diabetic Ketoacidosis (Chapter 354) - AAP Publications", "detail": "publications.aap.org", "url": "https://publications.aap.org/pediatriccare/book/348/chapter/5788504/Diabetic-Ketoacidosis-Chapter-354", "authors": "publications.aap.org", "host": "publications.aap.org", "snippet": "Insulin is essential to correct the metabolic disturbances present in children with DKA. Intravenous insulin therapy should be initiated after starting fluid", "score": 0.4302197 }, { "number": 13, "title": "Managing Diabetic Ketoacidosis in Children", "detail": "www.annemergmed.com", "url": "https://www.annemergmed.com/article/S0196-0644(21)00160-8/fulltext", "authors": "www.annemergmed.com", "host": "www.annemergmed.com", "snippet": "When serum glucose levels drop below 300 mg/dL (16.7 mmol/L), dextrose should be added to the intravenous fluids without changing the insulin", "score": 0.4187688 }, { "number": 14, "title": "[PDF] Clinical Practice Guidelines and Standards of Care of Diabetes ...", "detail": "extranet.who.int", "url": "https://extranet.who.int/ncdccs/Data/sdn_D1_final_Sudan_Diabetes_Guideline_2011%20(2).pdf", "authors": "extranet.who.int", "host": "extranet.who.int", "snippet": "of DKA is regular insulin.  Low dose insulin effectively corrects metabolic acidosis without precipitating rapid declines in plasma osmolality, glucose and potassium.  Give an intravenous bolus of 0.1 units/kg followed by a continuous infusion of 0.1 units/kg  Monitor blood glucose hourly, using ", "score": 0.58721006 }, { "number": 15, "title": "Pemphigus Vulgaris Complicated by SGLT-2 Inhibitor Associated Euglycemic Diabetic Ketoacidosis | ACS", "detail": "www.facs.org", "url": "https://www.facs.org/for-medical-professionals/news-publications/journals/case-reviews/issues/v5n5/12-stevens-diabetic-ketoacidosis", "authors": "www.facs.org", "host": "www.facs.org", "snippet": "Subsequently, the patient’s clinical condition steadily improved. By admission day five, his serum beta-hydroxybutyrate level decreased to 59.3 mg/dL, and his serum pH normalized to 7.41. The anion gap closed to 14 mEq/L by the sixth day, and urinalysis was negative for ketones by the seventh day. A", "score": 0.5367749 }, { "number": 16, "title": "[PDF] Pemphigus Vulgaris Complicated by SGLT-2 Inhibitor Associated ...", "detail": "www.facs.org", "url": "https://www.facs.org/media/ze5da444/12-stevens-diabetic-ketoacidosis.pdf", "authors": "www.facs.org", "host": "www.facs.org", "snippet": "Following intubation, the patient was transferred to the surgical intensive care unit (SICU). His anion gap progres­ sively increased from 27 to 38 mEq/L. While his blood glucose rose modestly to 210 mg/dL, urinalysis indicated 2+ ketones, and serum beta-hydroxybutyrate levels were markedly elevated", "score": 0.34866783 }, { "number": 17, "title": "Early subcutaneous basal insulin with intravenous insulin infusion for diabetic ketoacidosis management: A systematic review and meta‐analysis of randomised controlled trials - PMC", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12803681", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "adverse clinical consequences. These findings support the safe use of early SC basal insulin during acute DKA management, in parallel with careful monitoring of potassium levels as recommended by standard guidelines. [...] basal insulin with IVII during DKA management does not appear to increase the", "score": 0.756376 }, { "number": 18, "title": "Improving Intravenous and Subcutaneous Insulin Overlap During Treatment of Diabetic Ketoacidosis: A Quality Improvement Project", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11141259", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "A similar reduction in rates of posttransition hypoglycemia (6.4%) compared with a previous study using an EMR-based BPA to alert ICU providers that DKA had resolved (7%) was observed.9 This can be attributed to increased focus on the timing of IV and SC insulin overlap and enhanced accessibility to", "score": 0.69672287 }, { "number": 19, "title": "Success of Insulin Infusion Transitions in Moderate to Severe Diabetic Ketoacidosis With Transition Anion Gap of Less Than or Equal to 12 mEq/L Versus Greater Than 12 mEq/L", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11097940", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "Due to these metabolic derangements, the management of DKA centers on fluid replacement, insulin therapy, and electrolyte supplementation.1 Fluid resuscitation should be initiated immediately using crystalloid fluids, with guidelines recommending correction of estimated deficits within the first 24 ", "score": 0.6685563 }, { "number": 20, "title": "Management of adult diabetic ketoacidosis - PMC - NIH", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4085289", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "## .\n\n Administer priming insulin bolus at 0.1 U/kg and initiate continuous insulin infusion at 0.1 U/kg/h. Measure bedside glucose every 1 hour to adjust the insulin infusion rate.\n\n Avoid hypoglycemia during the insulin infusion by initiating dextrose-containing fluids and/or reduction of insu", "score": 0.63288915 }, { "number": 21, "title": "Diabetic Ketoacidosis - Endotext - NCBI Bookshelf", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/books/NBK620701", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov", "snippet": "For patients on long-acting insulin before admission, basal insulin can be continued during the administration of the IV insulin infusion, which will later enable the transition to a SC basal bolus regimen. In the newly diagnosed patients, basal insulin is initiated at 0.15–0.3 units/kg. Once DKA ha", "score": 0.5832277 }, { "number": 22, "title": "Basal insulin for the management of diabetic ketoacidosis", "detail": "pubmed.ncbi.nlm.nih.gov", "url": "https://pubmed.ncbi.nlm.nih.gov/28864157", "authors": "pubmed.ncbi.nlm.nih.gov", "host": "pubmed.ncbi.nlm.nih.gov", "snippet": "by L Barski · 2018 · Cited by 49 — These studies reveal that co-administration of basal insulin in combination with an insulin infusion in the acute management of DKA is feasible.Read more", "score": 0.4719782 }, { "number": 23, "title": "Diabetes and Hypertension Management Manual 15 Mar 2011", "detail": "extranet.who.int", "url": "https://extranet.who.int/ncdccs/Data/DMA_B6_Diabetes%20and%20Hypertension%20Management%20Manual%2015%20Mar%202011-%20Final2[3].pdf", "authors": "extranet.who.int", "host": "extranet.who.int", "snippet": "constipation. • Advantages: Good for elderly diabetics. • Disadvantages: weight gain. Human Insulin(first line drug) • Dosage and Administration: Insulin is administered subcutaneously. Regular insulin may be given IM or IV if needed. Dosage is highly variable. • Indications: Diabetes Mellitus Types", "score": 0.38984904 }, { "number": 24, "title": "MANAGING DIABETES IN SAINT LUCIA - Extranet Systems", "detail": "extranet.who.int", "url": "https://extranet.who.int/ncdccs/Data/LCA_D1_SLUDiabetes2006.pdf", "authors": "extranet.who.int", "host": "extranet.who.int", "snippet": "therapy - Recurrent hypoglycaemia - Metabolic instability characterized by frequent swings between hypoglycaemia and hyperglycaemia - Recurrent diabetic ketoacidosis in the absence of trauma and infection - Uncontrolled diabetes in pregnancy • Institution of intensive insulin regimes including insul", "score": 0.27886564 } ], "publishedAt": "2026-09-15T22:04:14.539674+00:00", "updatedAt": "2026-09-15T22:04:14.539674+00:00", "readingMinutes": 4, "slug": "dka-transition-to-subcutaneous-insulin" }